PDS Biotechnology Corporation — FY2019 Form 10-K
Reporting period: Fiscal year ended December 31, 2019. Although the request identifies Q4 2019, this is an annual report. PDS is a clinical-stage biopharmaceutical company developing cancer immunotherapies based on its Versamune platform. It has no approved products and has generated no product revenue.
Financial results and liquidity
| Metric | 2019 | 2018 |
|---|---|---|
| Product revenue | None | None |
| Research and development expense | $6.10 million | $0.83 million |
| General and administrative expense | $10.98 million | $2.79 million |
| Total operating expenses | $21.03 million | $3.65 million |
| Loss from operations | $21.03 million | $3.65 million |
| Net loss | $7.00 million | $3.84 million |
| Net cash used in operating activities | $18.07 million | $1.57 million |
The 2019 net loss includes a $13.33 million bargain-purchase gain from the March merger; it therefore does not reflect the scale of operating expenses. Operating cash use rose substantially year over year, attributed to higher development and public-company costs, merger expenses, and payments of liabilities accumulated before the merger. Cash flow from investing activities was $29.38 million, primarily cash acquired in the merger.
At December 31, 2019, cash and cash equivalents were $12.16 million; current assets were $14.47 million and current liabilities were $2.79 million. Total liabilities were $2.79 million, with no convertible notes payable outstanding at year-end. The company reported an accumulated deficit of $28.94 million. No meaningful revenue margin is available because there were no product sales.
In February 2020, PDS sold 10 million shares at $1.30 per share, receiving approximately $11.9 million net. Management said cash resources, including these proceeds, were expected to fund operations and research and development for at least 12 months from the report date. It cautioned that projections may prove inaccurate and additional financing may be needed. The filing reports no off-balance-sheet arrangements.
Material changes and notable items
- Research and development spending increased by $5.27 million, mainly from clinical-study costs and personnel. General and administrative expense increased by $8.19 million, including personnel, stock compensation, insurance, legal, and facility costs.
- The March 2019 reverse merger made Private PDS the accounting acquirer; 2018 comparative results reflect Private PDS, not the legacy Edge business. The merger brought approximately $29.1 million of cash onto the balance sheet and generated the bargain-purchase gain.
- PDS recorded a $2.97 million impairment of the acquired EG-1962 in-process research and development asset after partner interest diminished; the company said it was no longer pursuing partners for the legacy program. It also recorded $0.98 million in lease termination and disposal costs related to an office move.
- The company corrected immaterial errors in the presented 2018 financial statements, including classification and timing of certain expenses, equity, and debt-extinguishment accounting. Management said the errors did not require amendments to previously filed reports.
- Financial statements reported a $7.00 million net loss, while the statement of operations displays basic and diluted net loss per share as positive $1.44. The sign presentation appears inconsistent and should be checked against the filed statements.
Business progress, outlook, and risks
PDS0101 completed a 12-patient Phase 1 study. The company reported no dose-limiting toxicities at doses up to 10 mg and selected approximately 3 mg for further studies. A retrospective analysis found complete regression of precancerous lesions in 6 of 10 evaluable patients; responders were reported disease-free through the two-year evaluation. These are early-stage findings, and the filing cautions that early results may not predict later clinical outcomes.
PDS planned three PDS0101 Phase 2 studies, all expected to start in the first half of 2020: a 96-patient first-line combination study with Merck’s KEYTRUDA in HPV16-positive recurrent or metastatic head and neck cancer; an approximately 30-patient NCI study combining PDS0101 with M7824 and NHS-IL12 for advanced HPV-associated cancers; and a cervical-cancer study with chemoradiotherapy, subject to a definitive agreement. The KEYTRUDA study planned a safety review after the first 12 patients and an interim analysis in the second half of 2021. Other pipeline candidates include PDS0102, PDS0103, and PDS0104; clinical initiation for these programs depends on additional financing.
Management’s central outlook is continued development spending and operating losses, with no near-term product revenue expected. PDS relies on contract manufacturers, research organizations, and clinical collaborators, and has no commercial-scale manufacturing or sales infrastructure. Key risks include clinical and regulatory failure or delay, financing needs and potential shareholder dilution, competition, intellectual-property challenges, dependence on third parties, and uncertain future coverage and reimbursement. The filing also highlights possible COVID-19-related delays to trials, manufacturing, and access to capital.
Management concluded that internal control over financial reporting was ineffective at year-end because of material weaknesses in four COSO components, including insufficient technical accounting resources and weaknesses in risk assessment, information flow, and transaction-level controls. Remediation was ongoing. The independent auditor issued an unqualified opinion on the financial statements but did not audit internal-control effectiveness. The filing reports no material pending legal proceeding.
Important facts for investors to verify
- Whether the planned Phase 2 trials began on schedule and what enrollment, safety, and efficacy data subsequently showed.
- Whether the reported 6-of-10 lesion regression result is confirmed in larger, prospectively designed studies.
- Cash burn after year-end, the actual runway following the February 2020 offering, and the timing and terms of any further financing.
- The positive $1.44 per-share loss presentation and the reported accumulated-deficit figures, including differences elsewhere in the filing’s narrative.
- Progress in remediating material weaknesses and whether financial reporting controls were later determined effective.
- The impact of the reverse merger on comparisons, and the consequences of the EG-1962 impairment and other merger-related accounting items.